DevelopmentPipeline
Paradigm Biopharmaceuticals is focused on developing therapies that address areas of significant unmet medical need. Our development pipeline reflects a commitment to advancing treatments that may improve patient outcomes across a range of serious and chronic conditions, with a focus on diseases where better therapeutic options are urgently needed.
What do the stages mean?
Proof of concept›Phase 1›Phase 2›Phase 3›Registration
ReachedNowNot yet
- Proof of concept
- Laboratory or animal work, before any testing in people.
- Phase 1
- A first study in people, looking at safety and dosing.
- Phase 2
- A study in people who have the condition.
- Phase 3
- A large controlled study, run to support a regulatory submission.
- Registration
- Assessment by a medicines regulator. No Paradigm programme is at this stage.
- Active
- Work is happening now.
- Completed
- The study has finished. What happens next is on the row.
- Exploratory
- Preclinical work, or a programme under review.
Showing all 8 programmes.
No Paradigm programme is at Phase 1.
No Paradigm programme is at Registration.
Knee osteoarthritis
ActiveZilosul® (injectable PPS)
PARA_OA_012 · NCT06917404
- Trial start
- 29 May 2025
- Participants
- 538 dosed, against a 466 target
- Sites
- 65 across four countries
- Enrolment
- Completed 15 June 2026
- Next milestone
- Interim analysis, September 2026
- Topline
- Q1 2027
- Designation
- FDA Fast Track, April 2022
MPS VI
CompletedInjectable PPS
PARA_MPSVI_001 · RBR-2tz9dky
- Design
- 24-week randomised, double-blind, placebo-controlled
- Participants
- 12, all on enzyme replacement therapy
- Sites
- Two, Brazil
- Enrolment began
- August 2021
- Completion
- Declared at the November 2024 AGM
- Designation
- EMA orphan EU/3/20/2315
MPS I
CompletedInjectable PPS
Open-label Phase 2
- Design
- Open-label, single centre, 48 weeks
- Participants
- Four
- Published
- J Inherit Metab Dis, 2024
- What next
- Paradigm is seeking a partner to progress it
Ross River virus
CompletedPentosan polysulfate sodium
ACTRN12617000893303
- Design
- Pilot study, PPS in RRV-induced arthralgia
- Ran
- 25 July 2017 – 5 November 2018
- Published
- BMC Musculoskeletal Disorders, March 2021
- What next
- Current mention is compassionate access only
Inflammatory arthritis
ExploratoryPentosan polysulfate sodium
Label under review. V1 called this row “AR”, which on Paradigm’s own pages means allergic rhinitis.
View programme →
Chikungunya
ExploratoryPentosan polysulfate sodium
- Model
- Chikungunya-infected mice (preclinical)
- Published
- PLOS One, 2021
- Human trials
- None to date
ARDS
ExploratoryPentosan polysulfate sodium
- Model
- Influenza-induced ARDS, mouse (preclinical)
- Collaboration
- Menzies Health Institute Queensland
- Published
- Frontiers in Immunology, 9 February 2023
HFpEF
ExploratoryPentosan polysulfate sodium
- Model
- ZSF-1 obese rat (preclinical)
- Collaboration
- Center for Heart Failure Research, University of Oslo
- Human trials
- None to date
Zilosul® is an investigational product, not approved for sale or available for prescription. Stages shown are the most advanced study reached in each indication.
Osteoarthritis
Recognising the pressing need for new, safe, and effective treatments for the symptoms and underlying disease pathology of OA, Paradigm is developing PPS for OA under the trademark, Zilosul®.
Programmes- —Knee osteoarthritis, Phase 3

Lysosomal Storage Disease
Lysosomal storage diseases are a group of rare inherited disorders that affect the body’s ability to break down and recycle certain substances within cells. Over time, this build-up can cause progressive damage to organs, tissues and the nervous system. Because many of these conditions are lifelong, complex and currently have limited treatment options, they represent an important area for continued research and therapeutic development.
Programmes- —MPS VI, Phase 2
- —MPS I, Phase 2

Inflammatory Arthritis
Paradigm's inflammatory arthritis portfolio is focused on therapies designed to modulate inflammation while supporting joint health through complementary mechanism of action.
Programmes- —Ross River virus, Phase 2a
- —Inflammatory arthritis, proof of concept
- —Chikungunya, proof of concept

Respiratory
Respiratory diseases affect the lungs and airways, making it harder for people to breathe and maintain normal daily activity. These conditions can range from chronic inflammatory diseases to severe and progressive lung disorders, many of which place a major burden on patients, families and healthcare systems. Exploring new treatment options in respiratory disease is important because improved therapies may help reduce symptoms, prevent disease progression and support better long-term quality of life.
Programmes- —ARDS, proof of concept

Cardiovascular
Paradigm has successfully completed a translational preclinical study in the industry-standard ZSF-1 obese rat model of heart failure with preserved ejection fraction (HFpEF). Conducted in collaboration with the Center for Heart Failure Research and the Institute for Experimental Medical Research at the University of Oslo, the study demonstrated improved diastolic cardiac function and preservation of myocardial tissue architecture through modulation of extracellular matrix remodelling. These findings provide compelling proof-of-concept supporting the continued evaluation of PPS as a potential treatment for HFpEF.
Programmes- —HFpEF, proof of concept
